细胞因子配体3和绝经后骨质疏松症严重程度相关性研究

目的 探讨绝经后骨质疏松症患者血清细胞因子配体3(CCL3)水平是否与疾病严重程度相关。方法 82例绝经后骨质疏松症妇女，76例绝经后非骨质疏松症妇女，80例育龄健康妇女。采用双能X线骨密度仪测定全髋、股骨颈和腰椎L1-L4骨密度；使用商用酶联免疫吸附测定试剂盒检测血清CCL3水平；同时检测血清炎症细胞因子白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和1型交联的羧基末端端肽(CTX-1)和抗酒石酸酸性磷酸酶5b(TRACP-5b)。视觉模拟评分和OSwestry残疾指数评分用于评估临床严重程度。结果 绝经后骨质疏松症组患者血清CCL3水平明显高于绝经后非骨质疏松症组[(40.9±15.1) pg/mL vs (24.2±8.7) pg/mL，P＜0.001]和对照组[(40.9±15.1) pg/mL vs (23.9±9.1) pg/mL，P＜0.001]。血清CCL3水平与全髋(r=-0.345，P=0.002)、股骨颈(r=-0.329，P=0.003)和腰椎L1-L4(r=-0.354，P =0.001)的骨密度呈负相关，与视觉模拟评分(r=0.413，P＜0.001)和OSwestry残疾指数(r=0.360，P＜0.001)呈正相关。此外，血清CCL3水平与肿瘤坏死因子-α(r=0.305，P=0.005)、白细胞介素-6(r=0.288，P=0.008)、CTX-1(r=0.371，P＜0.001)和TRACP-5b(r=0.317，P=0.004)密切相关。在调整了体重指数和年龄后，所有的相关性仍然显著。结论 CCL3可能是一种有用的生物标志物，可用于预测绝经后骨质疏松症的病情严重程度。

Correlation between cytokine ligand 3 and the severity of postmenopausal osteoporosis

Objective To investigate if serum cytokine ligand 3(CCL3) levels correlated with disease severity in postmenopausal osteoporotic women. Methods Eighty-two postmenopausal osteoporotic women, 76 postmenopausal non-osteoporotic women, and 80 healthy women of childbearing age were recruited. Bone mineral density of the total hip, femoral neck, and L1-L4 spine was assessed using dual-energy X-ray absorptiometry. Serum CCL3 level was examined using a commercial enzyme-linked immunosorbent assay kit. Serum inflammatory cytokine interleukin-6, tumor necrosis factor-alpha, and the bone metabolic markers, carboxy-terminal crosslinked and tartrate-resistant acid phosphatase 5b were also examined. Visual analogue scale and the Oswestry disability index were utilized to assess the clinical severity. Results Patients in the postmenopausal osteoporotic group had significantly increased serum CCL3 levels compared with those in both the postmenopausal non-osteoporotic group (40.9±15.1 pg/mL vs 24.2±8.7 pg/mL, P<0.001) and control group (40.9±15.1 pg/mL vs 23.9±9.1 pg/mL, P<0.001). Serum CCL3 levels were negatively correlated with bone mineral density at the total hip (r=-0.345, P =0.002), femoral neck (r=-0.329, P=0.003), and L1-L4 lumbar spine (r=-0.354, P=0.001),but were positively correlated with visual analogue scale scores (r=0.413, P<0.001) and the Oswestry disability index (r=0.360, P<0.001). Moreover, serum CCL3 levels were closely correlated with increased tumor necrosis factor-alpha (r=0.305, P=0.005), interleukin-6 (r=0.288, P=0.008), tartrate-resistant acid phosphatase 5b (r=0.371, P<0.001), and carboxy-terminal crosslinked (r=0.317, P=0.004) levels. All correlations were still significant after adjusting for both body mass index and age. Conclusion CCL3 may be a useful biomarker that can be used to predict disease severity of postmenopausal osteoporosis.